Imaging of 212Pb in mice with a clinical SPECT/CT

EJNMMI Physics

Short Communication

Asta Juzeniene¹  Caroline Stokke²  Monika Kvassheim³  Anna Julie Kjøl Tornes⁴  Mona-Elisabeth R. Revheim⁵ 

[1] Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;Department of Physics, University of Oslo, Oslo, Norway;Division of Radiology and Nuclear Medicine, Department of Physics and Computational Radiology, Oslo University Hospital, Oslo, Norway;Department of Physics, University of Oslo, Oslo, Norway;Division of Radiology and Nuclear Medicine, Department of Physics and Computational Radiology, Oslo University Hospital, Oslo, Norway;Faculty of Medicine, University of Oslo, Oslo, Norway;Faculty of Medicine, University of Oslo, Oslo, Norway;Department of Radiation Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway;ARTBIO AS, Oslo, Norway;Faculty of Medicine, University of Oslo, Oslo, Norway;Division of Radiology and Nuclear Medicine, Department of Nuclear Medicine, Oslo University Hospital, Oslo, Norway;The Intervention Centre, Division of Technology and Innovation, Oslo University Hospital, Oslo, Norway;

关键词: Lead-212;    Pb;    Alpha;    Therapy;    Imaging;    SPECT;    Preclinical;    Phantom;   

DOI  :  10.1186/s40658-023-00571-6

 received in 2023-03-07, accepted in 2023-08-07,  发布年份 2023

来源: Springer

【 摘 要 】

ctIntroduction212Pb is a promising radionuclide for targeted alpha therapy. Here, the feasibility of visualising the tumour uptake and biodistribution of 212Pb-NG001 in mice with a clinical SPECT/CT scanner was investigated.MethodsA mouse phantom with 212Pb was imaged with a clinical- and a preclinical SPECT/CT scanner. Different acquisition and reconstruction settings were investigated on the clinical system (Siemens Symbia Intevo Bold). Two athymic nude mice carrying PC-3 PIP prostate cancer tumours of 235–830 μl received 1.44 MBq of 212Pb-NG001 and were imaged 2, 6, and 24 h post-injection on the clinical SPECT/CT with a Medium Energy collimator and a 40% energy window centred on 79 keV. All acquisition times were 30 min, except the mouse imaging 24 h post-injection which was 60 min. After the final imaging, the organs were harvested and measured on a gamma counter to give an indication of how much activity was present in organs of interest at the last imaging time point.ResultsFour volumes in the mouse phantom of ~ 300 μl with 246–303 kBq/ml of 212Pb were distinguishable on images acquired with the clinical SPECT/CT with a high number of reconstruction updates. With the preclinical SPECT, the same volumes were easily distinguished with 49 kBq/ml of 212Pb. Clinical SPECT/CT images of the mice revealed uptake in tumours and bladders 2 h after injection and in tumours containing down to approximately 15 kBq/ml at 6 and 24 h after injection.ConclusionAlthough the preclinical scanner should be used preferentially in biodistribution studies in mice, the clinical SPECT/CT confirmed uptake in small volumes (e.g. ~ 300 μl volume with ~ 250 kBq/ml). Regardless of system, the resolution and sensitivity limits should be carefully determined, otherwise false negative or too low uptakes can be wrongly interpreted.

【 授权许可】

CC BY   
© Springer Nature Switzerland AG 2023

【 图 表 】

Fig. 16